Immunopathology of American cutaneous leishmaniasis. Modulation of MHC class II gene products by keratinocytes before and after glucantime therapy.
Epidermal changes from 32 cutaneous and 3 mucosal American cutaneous leishmaniasis (ACL) active lesions were studied for HLA-DR, -DQ and -DP expression, Langerhans cells and lymphocyte infiltration. In addition to a DR and DQ positivity at the surface of the cells of the inflammatory infiltrate, a strong reaction for DR antigens was detected on keratinocytes. Hyperplasia of Langerhans cells was present in all cutaneous lesions and epidermis was infiltrated by T lymphocytes. When healed lesions of 14 of these subjects were re-biopsied 1 to 12 months after the end of pentavalent antimonial therapy, MHC class II antigens could no longer be seen on keratinocytes. Our data represent evidence for the reversibility of the abnormal HLA-DR expression by keratinocytes in ACL after Glucantime therapy or spontaneous scar formation, demonstrating that this expression is restricted to the period of active lesions. The present findings can be regarded as an indirect evidence that keratinocytes may be involved in the immunopathology of ACL.
Pirmez
C
C
Hospital Evandro Chagas-FIOCRUZ, Rio de Janeiro, RJ, Brasil.
Oliveira-Neto
M P
MP
Grimaldi Júnior
G
G
Savino
W
W
D000981:Antiprotozoal Agents / Q000627:therapeutic use; D005802:Genes, MHC Class II; D006682:HLA-DP Antigens / Q000032:analysis*; D006683:HLA-DQ Antigens / Q000032:analysis*; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D015603:Keratinocytes / Q000276:immunology*; D007896:Leishmaniasis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D006682:HLA-DP Antigens; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate